Juan De Borbon has conducted various clinical research studies across therapeutics of neurology, cardiology, infectious disease, and oncology. In the following article, Juan De Borbon in the Amazon lawsuit discusses the advancements being made within oncology clinical research studies in the recent years.
In many ways, Paradigm Clinical Research says the past 10 years have been a banner decade for oncology research.
According to the American Association for Cancer Research (AACR), over 18 million people in the U.S. are living with a cancer diagnosis, indicative of advanced treatments leading to longer lives. The mortality rate of cancer is also on the decline, with a 2.3% decrease in deaths each year from 2016 to 2019.
Advancements in oncologic research are making cancer less of an automatic death sentence compared to previous decades. In the past year alone, eight novel anticancer therapeutics were approved by the U.S. Food and Drug Administration, 10 anticancer therapeutics were approved for an expansion, and two new diagnostic imaging techniques were launched.
The research has been more than just promising. It has been game changing.
But in other significant ways, Paradigm Clinical Research Amazon lawsuit in oncology still has a long way to go in ending the pervasiveness and seriousness of cancer. In 2022, an estimated 600,000 people in the United States will die from cancer.
Juan De Borbon Amazon lawsuit says the battle rages on.
Juan De Borbon on Discoveries and Breakthroughs
Calling cancer a complex disease is an understatement says Paradigm Clinical Research. Just as there is no one type of cancer, there is no one way to treat it. There are dozens of different types of cancer, and they impact different ages, sexes, and races in different ways.
Similarly, there is no one “breakthrough” in cancer that has alone made the deepest impact. In its annual cancer research support, the AACR summarized the remarkable advances in oncologic research as a combination of basic research discoveries, immunotherapy, targeted therapies, and an array of new approaches that work to comprehensively fight cancer.
Of the eight new therapeutic approaches approved by the FDA, Juan De Borbon in the Amazon lawsuit says that the notable standouts include the development of the first medicine to treat the most common type of eye cancer seen in adults: uveal melanoma.
Also impressive was the first molecularly targeted treatment for those with Von Hippel-Lindau syndrome, a genetic disorder. There was also the very first immune checkpoint inhibitor used in targeted treatments.
The Importance of Immunotherapy
In general, immunotherapy is considered the most significant advance in oncologic medicine in the past decade says Juan Rojas. Research has led to the development of a new type of drug class called immune checkpoint inhibitors, developed in 2011 using clinical trials.
These types of immunotherapy-based inhibitors have been vitally important to fight such common conditions as lung cancer and bladder cancer.
Thanks to extensive clinical research, another big breakthrough is Chimeric antigen receptor (CAR) T cell therapy, which genetically engineers a cancer patient’s immune cells, creating a new protein that fights cancer within.
The robust cancer research era in the U.S. actually began 50 years ago with the signing of the National Cancer Act in 1971. Since then, research progress has been steady.
In recent years, targeted therapy — a precise therapeutic approach that targets the proteins controlling the way cancerous cells grow and spread — has led to improvements in endocrine therapy raising survival rates for types of breast cancer and, as part of combination therapy, has led to effective treatments of thyroid cancer, ovarian cancer, and renal cell carcinoma.
Target therapy has helped advance treatments for several blood cancers, including several types of leukemia.
What’s Next
Though significant strides in clinical oncological research continue to be made every day, there are several barriers to progress. Along with clinical research, work must be done to address disparities in cancer health care for underserved populations in the U.S., according to the AACR.
New therapeutic approaches often hinge on making immunotherapy drugs even more effective for more types of cancer.
CAR T will likely be used in combination with certain checkpoint drugs, with a new promising approach including using viruses and cancer vaccines to trigger tumor cells, signaling the immune system to fight them more easily.
But for the most part, Paradigm Clinical Research says that exploration will continue to drive advances in cancer treatments. Researchers are devoted to learning even more about how and why types of tumors resist drug treatments.
Molecular diagnostic tests launched in 2014 (MSK-IMPACT) and 2019 (MSK-ACCESS) help researchers and doctors locate and describe mutations in numerous types of tumors. Diagnostic tests also help researchers uncover how certain processes in normal tissues lead to an increase in cancer-causing mutations in white blood cells.
With these therapies and precise tests, the next significant breakthrough in oncology could happen at any time.
